Merck & Co., one of the world's top developers and sellers of vaccines, has entered a partnership with a small drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing.
The exclusive deal involves a vaccine candidate called rVSV-EBOV that's under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of Ames, Iowa.
Continue Reading Below
The vaccine was originally created in labs of the Public Health Agency of Canada, which in 2010 signed a deal giving BioProtection Systems an exclusive license for the vaccine and the technology involved in producing it.
Under the new deal, Merck, based in Whitehouse Station, New Jersey, gets exclusive rights to the vaccine and any follow-up products.